A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement (Nexobrid®) in Burns Following the 2020 Updated European Consensus Guidelines - PubMed (original) (raw)

Multicenter Study

A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement (Nexobrid®) in Burns Following the 2020 Updated European Consensus Guidelines

Tomasz Korzeniowski et al. Med Sci Monit. 2022.

Abstract

BACKGROUND The supplementary treatment of burns with enzymatic debridement with Nexobrid® was approved in Europe in 2013. The 2017 European consensus guidelines on the removal of eschar in burns by bromelain-based enzymatic debridement were updated in 2020. This questionnaire-based study aimed to obtain a consensus from 5 Polish burns centers on eschar removal by Nexobrid® in burns following the 2020 updated European consensus guidelines. MATERIAL AND METHODS A panel of 5 experts representing the leading burn treatment centers in Poland (Cracow, Gryfice, Siemanowice Śląskie, Poznań, and Łęczna) was convened. A modified Delphi process was implemented with panel member selection, literature review, 2 rounds of voting in which panelists were asked to evaluate the European consensus and Polish consensus building by data analysis, statements preparation, final voting, and manuscript drafting. RESULTS The knowledge and experience of experts from Poland's leading burn centers resulted in the development of guidelines, formulated as 24 statements representing the following areas: indications and usage, pain management, application principles, post-enzymatic debridement wound dressing, and early and long-term outcomes. An analysis of the 7-point Likert scale polls revealed that 23 of the 24 statements achieved 100% consensus. CONCLUSIONS The findings from this survey from 5 major centers in Poland supported the main recommendations from the 2020 updated European consensus guidelines on the removal of eschar in burns by Nexobrid® and may serve as a practical guide for surgeons who care for patients with burns in this country.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

References

1. Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006;32(2):145–50. -PubMed
1. Gacto-Sanchez P. Surgical treatment and management of the severely burn patient: Review and update. Med Intensiva. 2017;41(6):356–64. -PubMed
1. Loo YL, Goh BKL, Jeffery S. An overview of the use of bromelain-based enzymatic debridement (Nexobrid®) in deep partial and full thickness burns: Appraising the evidence. J Burn Care Res. 2018;39:932–38. -PubMed
1. Rosenberg L, Krieger Y, Silberstein E, et al. Selectivity of a bromelain based enzymatic debridement agent: A porcine study. Burns. 2012;38:1035–40. -PubMed
1. Rosenberg L, Krieger Y, Bogdanov-Berezovski A, et al. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014;40:466–74. -PubMed

A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement (Nexobrid®) in Burns Following the 2020 Updated European Consensus Guidelines - PubMed (original) (raw)